{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:42:16Z","timestamp":1773834136369,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.semnephrol.2006.09.006","type":"journal-article","created":{"date-parts":[[2008,9,21]],"date-time":"2008-09-21T13:22:07Z","timestamp":1222003327000},"page":"35-46","source":"Crossref","is-referenced-by-count":34,"title":["The Antiphospholipid Syndrome"],"prefix":"10.1016","volume":"27","author":[{"given":"Michael J.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerrold S.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2006.09.006_bib1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMra002974","article-title":"Anti-phospholipid syndrome","volume":"346","author":"Levine","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib2","series-title":"Rheumatology and the kidney","first-page":"132","article-title":"Renal involvement in the antiphospholipid syndrome","author":"Levine","year":"2001"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib4","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/art.20120","article-title":"The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus","volume":"50","author":"McClain","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib7","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib8","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2004-03-1107","article-title":"Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"de Laat","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis","volume":"105","author":"de Laat","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib10","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2005-05-1943","article-title":"Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change","volume":"107","author":"de Laat","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib11","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-08-2349","article-title":"Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies","volume":"101","author":"Raschi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V103507","article-title":"The intrarenal vascular lesions associated with primary antiphospholipid syndrome","volume":"10","author":"Nochy","year":"1999","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0272-6386(03)00352-4","article-title":"The expanding spectrum of renal diseases associated with antiphospholipid syndrome","volume":"41","author":"Fakhouri","year":"2003","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ard.2004.025759","article-title":"Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome","volume":"64","author":"Cervera","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.62.6.530","article-title":"Long term outcome of catastrophic antiphospholipid syndrome survivors","volume":"62","author":"Erkan","year":"2003","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.7326\/0003-4819-117-12-997","article-title":"Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis","volume":"117","author":"Ginsburg","year":"1992","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib21","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/1529-0131(200106)44:6<1466::AID-ART242>3.0.CO;2-C","article-title":"High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin","volume":"44","author":"Erkan","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib23","first-page":"S640","article-title":"APLASA study 2004 update: primary thrombosis prevention in asymptomatic aPL-positive patients with aspirin [abstract]","volume":"50","author":"Erkan","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib24","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1177\/096120339600500105","article-title":"Hydroxychloroquine use in the Baltimore lupus cohort: effects on lipids, glucose and thrombosis","volume":"5","author":"Petri","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.semnephrol.2006.09.006_bib25","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/ard.52.9.689","article-title":"Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment","volume":"52","author":"Derksen","year":"1993","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"Comparison of two intensities of warfarin for the prevention of recurrent of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.rdc.2005.09.004","article-title":"New treatments for antiphospholipid syndrome","volume":"32","author":"Erkan","year":"2006","journal-title":"Rheum Dis Clin North Am."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib31","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.semnephrol.2006.09.006_bib32","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.11332","article-title":"New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations","volume":"48","author":"Roubey","year":"2003","journal-title":"Arthritis Rheum."}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929506001161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929506001161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T23:12:55Z","timestamp":1631833975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929506001161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0270929506001161"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2006.09.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}